CD38 Exacerbates Focal Cytokine Production, Postischemic Inflammation and Brain Injury after Focal Cerebral Ischemia
Open Access
- 13 May 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (5) , e19046
Abstract
Converging evidence suggests that inflammatory processes significantly influence brain injury and clinical impairment in ischemic stroke. Although early studies suggested a key role of lymphocytes, recent data has emphasized the orchestrating function of innate immunity, i.e., macrophages and microglia. The bifunctional receptor and ectoenzyme CD38 synthesizes calcium-mobilizing second messengers (e.g., cyclic ADP-ribose), which have been shown to be necessary for activation and migration of myeloid immune cells. Therefore, we investigated the dynamics of CD38 in stroke and the impact of CD38-deficiency on cytokine production, inflammation and cerebral damage in a mouse model of cerebral ischemia-reperfusion. We show that the local expression of the chemokine MCP-1 was attenuated in CD38-deficient mice compared with wildtype mice after focal cerebral ischemia and reperfusion. In contrast, no significant induction of MCP-1 expression was observed in peripheral blood after 6 hours. Flow cytometry analysis revealed less infiltrating macrophages and lymphocytes in the ischemic hemisphere of CD38-deficient mice, whereas the amount of resident microglia was unaltered. An up-regulation of CD38 expression was observed in macrophages and CD8+ cells after focal cerebral ischemia in wildtype mice, whereas CD38 expression was unchanged in microglia. Finally, we demonstrate that CD38-deficiency decreases the cerebral ischemic injury and the persistent neurological deficit after three days of reperfusion in this murine temporary middle cerebral artery occlusion (tMCAO) model. CD38 is differentially regulated following stroke and its deficiency attenuates the postischemic chemokine production, the immune cell infiltration and the cerebral injury after temporary ischemia and reperfusion. Therefore CD38 might prove a therapeutic target in ischemic stroke.Keywords
This publication has 30 references indexed in Scilit:
- Combating innate inflammation: a new paradigm for acute treatment of stroke?Annals of the New York Academy of Sciences, 2010
- Modulation of the Postischemic Immune Response to Improve Stroke OutcomeStroke, 2010
- Nitroxyl exacerbates ischemic cerebral injury and oxidative neurotoxicityJournal of Neurochemistry, 2009
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and PathologyPhysiological Reviews, 2008
- T- and B-Cell-Deficient Mice with Experimental Stroke have Reduced Lesion Size and InflammationJournal of Cerebral Blood Flow & Metabolism, 2007
- Absence of the Chemokine Receptor CCR2 Protects Against Cerebral Ischemia/Reperfusion Injury in MiceStroke, 2007
- Role of T Lymphocytes and Interferon-γ in Ischemic StrokeCirculation, 2006
- CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokinesJournal of Leukocyte Biology, 2004
- Monocyte Chemoattractant Protein–1 Messenger RNA Expression in Rat Ischemic CortexStroke, 1995
- Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the ratJournal of Neuroimmunology, 1995